148 related articles for article (PubMed ID: 11062536)
1. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.
DeFeo-Jones D; Garsky VM; Wong BK; Feng DM; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Wai J; Senderak ET; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Freidinger R; Huff J; Oliff A; Jones RE
Nat Med; 2000 Nov; 6(11):1248-52. PubMed ID: 11062536
[TBL] [Abstract][Full Text] [Related]
2. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
[TBL] [Abstract][Full Text] [Related]
3. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
4. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
5. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
7. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
8. Inverted chemistry--from drug to prodrug.
Renner M
Trends Mol Med; 2001 Mar; 7(3):100. PubMed ID: 11286768
[No Abstract] [Full Text] [Related]
9. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
[TBL] [Abstract][Full Text] [Related]
10. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
12. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion.
Papo N; Braunstein A; Eshhar Z; Shai Y
Cancer Res; 2004 Aug; 64(16):5779-86. PubMed ID: 15313920
[TBL] [Abstract][Full Text] [Related]
13. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
Ravel D; Dubois V; Quinonero J; Meyer-Losic F; Delord J; Rochaix P; Nicolazzi C; Ribes F; Mazerolles C; Assouly E; Vialatte K; Hor I; Kearsey J; Trouet A
Clin Cancer Res; 2008 Feb; 14(4):1258-65. PubMed ID: 18281561
[TBL] [Abstract][Full Text] [Related]
14. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V
Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
[TBL] [Abstract][Full Text] [Related]
17. A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.
DeFeo-Jones D; Brady SF; Feng DM; Wong BK; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Pawluczyk JM; Wai J; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Garsky VM; Freidinger R; Oliff A; Jones RE
Mol Cancer Ther; 2002 May; 1(7):451-9. PubMed ID: 12479263
[TBL] [Abstract][Full Text] [Related]
18. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
[TBL] [Abstract][Full Text] [Related]
19. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
20. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]